

November 14, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd., Bhiwadi, a wholly owned subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from November 03rd to November 14th, 2025.

The inspection concluded with 9 observations. The observations are procedural in nature and will be responded to within the stipulated time.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl.: Annexure

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

Sr. No.	Particulars	Details
1	Name of the authority	US Food and Drug Administration (US FDA), USA
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	US FDA inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from November 3 to November 14, 2025.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	November 14, 2025
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The inspection concluded with 9 observations. The observations are procedural in nature and will be responded to within the stipulated time.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	This development will not have any impact on the existing operations of the Unit.

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com